The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models

Cancer Models ◽

Abstract 1077: Acquired neratinib resistance is associated with acquisition ofHER2andPIK3CAmutations and can be overcome using potent drug combinations in HER2-positive breast cancer models

10.1158/1538-7445.am2021-1077 ◽

2021 ◽

Author(s):

Jamunarani Veeraraghavan ◽

Ragini Mistry ◽

Sarmistha Nanda ◽

Sreyashree Bose ◽

Chia Chia Liu ◽

...

Keyword(s):

Breast Cancer ◽

Drug Combinations ◽

Her2 Positive ◽

Cancer Models ◽

Potent Drug ◽

Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models

10.1158/1538-7445.am2020-1911 ◽

2020 ◽

Author(s):

Jamunarani Veeraraghavan ◽

Ragini Mistry ◽

Sarmistha Nanda ◽

Vidyalakshmi Sethunath ◽

Martin Shea ◽

...

Keyword(s):

Breast Cancer ◽

Acquired Resistance ◽

Cross Resistance ◽

Her2 Positive ◽

Cancer Models ◽

Abstract P6-03-20: The development and characterization of novel HER2-positive breast cancer models of acquired neratinib resistance

10.1158/1538-7445.sabcs19-p6-03-20 ◽

2020 ◽

Author(s):

Neil T Conlon ◽

Alacoque Browne ◽

Laura Breen ◽

Alex J Eustace ◽

John Crown ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Cancer Models ◽

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models

BMC Medicine ◽

10.1186/1741-7015-10-80 ◽

2012 ◽

Vol 10 (1) ◽

Cited By ~ 51

Author(s):

Parul Gupta ◽

Sanjay K Srivastava

Keyword(s):

Breast Cancer ◽

Antitumor Activity ◽

Phenethyl Isothiocyanate ◽

Her2 Positive ◽

Cancer Models ◽

Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

10.1158/1538-7445.am2016-2130a ◽

2016 ◽

Cited By ~ 1

Author(s):

Sonia Palomeras ◽

Angel Diaz-Lagares ◽

Sarrats Ariadna ◽

Crujeiras Ana Belen ◽

Giro-Perafita Ariadna ◽

...

Keyword(s):

Breast Cancer ◽

Epigenetic Silencing ◽

Trastuzumab Resistance ◽

Her2 Positive ◽

Cancer Models ◽

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3239-5 ◽

2014 ◽

Vol 149 (2) ◽

pp. 373-383 ◽

Cited By ~ 23

Author(s):

N. Elster ◽

M. Cremona ◽

C. Morgan ◽

S. Toomey ◽

A. Carr ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapies ◽

Acquired Resistance ◽

Her2 Positive ◽

Preclinical Evaluation ◽

Cancer Models ◽

Abstract 4231: Enhanced antitumor efficacy of T-DM1 in combination with pertuzumab in HER2-positive breast cancer models

10.1158/1538-7445.am2014-4231 ◽

2014 ◽

Author(s):

Yuliang Sun ◽

Nandini Dey ◽

Jennifer Carlson ◽

Melissa Brammer ◽

Pradip De ◽

...

Keyword(s):

Breast Cancer ◽

Antitumor Efficacy ◽

Her2 Positive ◽

Cancer Models ◽

Review of treatment strategies for HER2 positive breast cancer and their implementation in a major Swiss hospital

10.1055/s-0040-1710671 ◽

2020 ◽

Author(s):

F Geissler ◽

M Vetter ◽

A Schoetzau ◽

C Montavon ◽

C Kurzeder ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Strategies ◽

Her2 Positive ◽

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis

10.26226/morressier.596dfd55d462b80292386fa4 ◽

2017 ◽

Author(s):

You-Jeong Seo

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Sequential Analysis ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Pik3ca Mutations ◽

Hypoxia up-regulates ID proteins in Luminal and HER2-positive breast cancer cell lines

10.26226/morressier.5b4709836f4cb30010951ad8 ◽

2018 ◽

Author(s):

Gloria Peiro Cabrera

Keyword(s):

Breast Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Breast Cancer Cell Lines ◽

Her2 Positive ◽

Id Proteins ◽

Positive Breast Cancer Cell ◽